Ardeshir Hakami-Kermani, MD

Closed

Photos

1 Gustave L Levy Pl Ste 310
New York, NY 10029

Ardeshir Hakami-Kermani, MD is an experienced thoracic surgeon with over 10 years of expertise in minimally invasive thoracic surgery, mediastinal staging, VATS-Lobectomy, and Sympathectomy. He is a board-certified thoracic surgeon in Denmark and has performed over 700 major cases, including more than 100 VATS-Lobectomies and over 400 minimal invasive mediastinal staging procedures. Dr. Hakami is fluent in English, Farsi, Danish, Swedish, and Norwegian, and has a dedication to perfection, excellence, and optimal patient care.

Dr. Hakami received his medical degree from Aarhus University Medical School in Denmark and completed residencies in General Surgery, Cardiothoracic, and Vascular Surgery at Odense University Hospital. He was appointed Assistant Professor of Surgery at the Department of Cardiothoracic and Vascular Surgery at Odense University Hospital, where he co-directed the Cardiothoracic Residency program and helped establish the Center of Excellence in Minimal Invasive Thoracic Surgery. Dr. Hakami also completed an advanced fellowship in General Thoracic Surgery at Mount Sinai Medical Center under the training of Dr. Raja Flores.

Generated from the website

Owner verified
See a problem?

You might also like

Joshua Brody, MD
Internal medicine practitioners

Joshua Brody, MD

Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies. Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology. Dr. Brody is committed to partnering with his patients to choose the most appropriate treatment approach that offers the best outcomes with excellent quality of life.
United StatesNew YorkNew YorkArdeshir Hakami-Kermani, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.